A B cell's receptor is an antibody fixed to its own surface. Unlike a T cell, it recognises whole shapes floating free, with no need for MHC. Most of what makes antibodies so good happens in a remarkable process inside the lymph node, which is natural selection, run in a few weeks.
Getting permission
A B cell in a lymph node meets its target, swallows it and displays the pieces on MHC class II. It's now effectively asking a question, and it can go no further until a helper T cell that recognises the same antigen answers it. The helper provides a signal through CD40 and cytokines. This double check is an important safety feature, because a self-reactive B cell seldom finds a self-reactive helper.
Then it has two possible paths.
- Quick and rough: some become plasma cells straight away, making mostly IgM. This provides early antibody, which isn't very strong.
- Slow and refined: others enter a germinal centre, and most of the high-quality antibody comes from these.
The germinal centre
Over weeks, and after some vaccines months, B cells cycle between two zones.
| Zone | What happens |
|---|---|
| Dark zone: mutate | Cells divide fast while an enzyme called AID introduces random changes into their antibody genes, at about a million times the normal rate. |
| Light zone: compete | Cells try to grab antigen held on the surface of supporting cells, and then show it to T follicular helpers. Those that grip best get the most help and survive. The others die. |
Winners return to the dark zone for another round. Most mutations are useless or harmful, so a great many cells die, but each round, the survivors bind slightly better.
This is called affinity maturation. It can raise an antibody's grip 100 to 1,000-fold or more over a response, which is why later antibodies are so much better than the early ones. It's also why a vaccine booster improves not only the amount of antibody but also its quality.
Class switching
Mostly just before they enter the germinal centre, B cells can change the tail of their antibody while keeping the same arms, so the target stays the same but the job changes. Cytokines from the helper decide the switch: IgG for most infections, IgA at mucosal surfaces and IgE for worms. See Antibodies.
People with hyper-IgM syndrome can't do this because a key signal is missing. They make only IgM, showing that the switch needs T cell help.
What comes out
- Plasma cells: antibody factories, each making around 2,000 molecules a second. Many live only days, but some settle into the bone marrow and go on for decades.
- Memory B cells: a small group waiting for the next meeting. They're quick to respond, and they can re-enter germinal centres to refine further.
Without T cell help
Some targets, including the sugar capsules of certain bacteria, have many repeating units that can directly set off a B cell. That's quick, but it gives mostly IgM, little refinement and poor memory. Young children barely respond in this way, which explains why conjugate vaccines are designed to link the sugar to a protein, to get T cells involved.
Rituximab removes B cells by targeting CD20. Plasma cells don't have CD20, so existing antibodies decline only slowly while new responses, including to vaccines, are blunted for months. It works well in some autoimmune diseases, which shows that B cells do more than make antibodies.
B cells mutate their antibody genes in the germinal centre, and only those that bind best survive. This is why antibodies get better with time and with each exposure.